FYI

This is to inform that the Health Sciences Authority (HSA) has suspended the sales of all registered oral nimesulide products. The suspension of sales has been prompted by Irish Medicines Board's recent suspension of all oral nimesulide-containing products. HSA has conducted a review of the safety profile of nimesulide and concluded that the risk-benefit balance of nimesulide is unfavourable because of the risk of severe hepatic reactions, as well as the availability of alternative drugs to treat the conditions that nimesulide is indicated for. Doctors are advised not to prescribe nimesulide to new patients and to review alternative treatment options for patients currently taking nimesulide.